This article assesses the clinical and prognostic value of VEGF and Ki-67 immunohistochemical markers in patients diagnosed with ovarian cancer. A total of 130 patients treated at the Tashkent Regional Branch of the Republican Oncology and Radiology Center between 2018 and 2022 were included in the study. Expression of the markers was evaluated using H-score and percentage index methods. Results demonstrated that high levels of VEGF and Ki-67 expression were significantly associated with increased recurrence risk (p<0.001). Kaplan–Meier survival analysis and Cox regression confirmed the independent prognostic significance of these markers. The potential for developing an immunohistochemical prognostic panel to guide individualized therapeutic strategies and determine the necessity of adjuvant therapy is discussed.

Ovarian cancer, VEGF, Ki-67

Prat J. A synopsis of the 2014 WHO classification of tumors of the female reproductive organs. Mod Pathol. 2015.

Bell D. et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011.

McCluggage WG. Morphological subtypes of ovarian carcinoma. Histopathology. 2011.

Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer. Am J Surg Pathol. 2010.

Köbel M. et al. Differences in tumor biology between histological subtypes of ovarian cancer. Int J Gynecol Pathol. 2014.

Yemelyanova A. et al. Immunohistochemical p53 staining in ovarian cancer. Mod Pathol. 2011.

Cannistra SA. Cancer of the ovary. N Engl J Med. 2004.

Ferrara N. VEGF: basic science and clinical progress. Endocr Rev. 2004.

Hlatky L, Hahnfeldt P. Clinical implications of angiogenesis in cancer. N Engl J Med. 1996.

American Cancer Society. Ovarian Cancer Statistics. 2023.